Genentech and NVIDIA enter into strategic AI research collaboration to accelerate drug discovery and development
Genentech, a member of the Roche Group has announced a multi-year strategic research collaboration with NVIDIA that couples Genentech’s artificial intelligence (AI) capabilities, extensive biological and molecular datasets, and research expertise with NVIDIA’s world-leading accelerated computing capabilities and AI to speed up drug discovery and development.
The collaboration is designed to significantly enhance Genentech’s advanced AI research programs by transforming its generative AI models and algorithms into a next-generation AI platform, expediting the discovery and delivery of novel therapies and medicines to people. The companies will join forces to accelerate and optimize Genentech’s proprietary machine learning (ML) algorithms and models on NVIDIA DGX Cloud, which provides a training-as-a-service platform built on dedicated NVIDIA AI supercomputing and software, including NVIDIA BioNemo for generative AI applications in drug discovery.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins